CoChat

Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus

Neumiller, Joshua J, Campbell, R Keith · 2009 · Annals of Pharmacotherapy
Cited by 63

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of liraglutide, a glucagon-like peptide 1 (GLP-1) analog for the treatment of type 2 diabetes mellitus. Data Sources: A MEDLINE search (1966–May 2009) was conducted for English-language articles using the terms glucagon-like peptide 1, incretin mimetic, NN2211, and liraglutide. Abstracts presented at the American Diabetes Association and European Association for the Study of Diabetes annual meetings in 2006, 2007, and 2008 were also searched for relevant data. Study Selection and Data Extraction: Articles pertinent to the pharmacology, pharmacokinetics, efficacy, and safety of liraglutide were reviewed. Data Synthesis: Liraglutide is a GLP-1 analog with pharmacokinetic properties suitable for once-daily administration. Clinical trial data from large, controlled studies demonstrate the effectiveness of liraglutide in terms of hemoglobin A 1c (A1C) reduction, reductions in body weight, and the drug's low risk for hypoglycemic events when used as monotherapy. Data also support benefits of liraglutide therapy on β-cell responsiveness to glucose, with animal and in vitro data indicating potential benefits in β-cell mass and neogenesis with liraglutide treatment. Liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and rosiglitazone for the treatment of type 2 diabetes. Additionally, comparative data with insulin glargine and exenatide therapy are available from Phase 3 trials providing practitioners valuable clinical data on which to base clinical decision making. Overall, liraglutide is well tolerated with dose-dependent nausea, vomiting, and diarrhea being the most commonly reported adverse events in clinical trials. Conclusions: Once-daily administration may provide a therapeutic advantage for liraglutide over twice-daily exenatide, with similar improvements in A1C and body weight observed when liraglutide was compared with exenatide. The glucose-dependent mechanism of insulin release with GLP-1 agonist therapy holds potential clinical significance in the management of postprandial hyperglycemic excursions, with minimal risk of hypoglycemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1345/aph.1m134

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 54

  1. 10.1210/jc.2002-021545 · DOI · Paper page
  2. Novo Nordisk. Liraglutide press releases. www.novonordisk.com/science/pipeline/liraglutide-press-releases.asp (accessed 2009 Mar 2).
  3. 10.2337/diacare.26.10.2929 · DOI · Paper page
  4. 10.3109/00365529609009147 · DOI · Paper page
  5. 10.1177/0145721706297451 · DOI
  6. 10.1152/ajpendo.00099.2005 · DOI · Paper page
  7. 10.1210/jc.2003-030738 · DOI · Paper page
  8. 10.1007/s00125-004-1342-6 · DOI · Paper page
  9. 10.2337/diabetes.50.3.609 · DOI · Paper page
  10. 10.1007/s001250050664 · DOI · Paper page
  11. 10.1210/endo-123-4-2009 · DOI · Paper page
  12. Willms B, 1996, J Clin Endocrinol Metab, 81, 327
  13. Nauck MA, 1997, Am J Physiol, 273, E981-8
  14. 10.2337/diabetes.49.5.741 · DOI · Paper page
  15. 10.2337/diabetes.48.12.2358 · DOI · Paper page
  16. 10.1002/dmrr.357 · DOI · Paper page
  17. 10.1038/nbt1115 · DOI · Paper page
  18. 10.1517/13543784.15.8.887 · DOI
  19. 10.2337/diab.44.9.1126 · DOI · Paper page
  20. 10.1021/jm9909645 · DOI · Paper page
  21. 10.1517/13543784.16.2.231 · DOI · Paper page
  22. Knudsen LB, 1999, Diabetologia, 42, A199
  23. Steensgaard DB, 2008, Diabetes, 57, A164
  24. Bjornsdottir I, 2008, Diabetologia, 51, S356
  25. Flint A, 2007, Diabetes, 56, A0545P
  26. Jacobsen LV, 2007, Diabetes, 56, A0513P
  27. 10.1177/0091270006288215 · DOI · Paper page
  28. 10.5414/CPP46273 · DOI · Paper page
  29. 10.1016/j.diabres.2008.03.018 · DOI
  30. 10.1111/j.1463-1326.2008.00861.x · DOI
  31. 10.2337/dc06-2593 · DOI · Paper page
  32. 10.2337/dc07-0310 · DOI · Paper page
  33. Vilsboll T, 2006, Diabetes, 55, A2007PO
  34. 10.1055/s-2006-924230 · DOI · Paper page
  35. 10.1177/0091270006288215 · DOI · Paper page
  36. 10.1111/j.1464-5491.2005.01567.x · DOI · Paper page
  37. 10.2337/diacare.27.8.1915 · DOI · Paper page
  38. 10.2337/diacare.27.6.1335 · DOI · Paper page
  39. 10.2337/diabetes.52.7.1786 · DOI · Paper page
  40. 10.1016/S0928-0987(03)00073-3 · DOI
  41. 10.2337/diabetes.51.2.424 · DOI · Paper page
  42. Marre M, 2008, Diabetes, 57, A4, 10.2337/db07-1569 · DOI
  43. Zinman B, 2008, Diabetologia, 51, S359
  44. Blonde L, Rosenstock J, Sesti G, Liraglutide: superior glycemic control vs exenatide when added to metformin and/or SU in type 2 diabetes. 2008 CDA/CSEM Professional Conference and Annual Meetings, abstract 107. www.diabetes.ca/files/for-professionals/conference-abstract-book.pdf (accessed 2009 Mar 6).
  45. 10.1038/sj.bjp.0705397 · DOI · Paper page
  46. 10.1152/ajpendo.00030.2002 · DOI · Paper page
  47. Hui H, 2006, Diabetes, 55, A1933
  48. 10.1677/JOE-08-0468 · DOI · Paper page
  49. 10.1111/j.1464-5491.2008.02484.x · DOI · Paper page
  50. Nauck MA, 2003, Diabetes, 52, A128
  51. 10.1517/14740330802432003 · DOI · Paper page
  52. Ahmad SR, 2008, N Engl J Med, 358, 1970
  53. 10.1016/j.clinthera.2006.05.006 · DOI
  54. 10.1111/j.1464-5491.2005.01567.x · DOI · Paper page

Cited by

See all 63

Metadata

Authors
Neumiller, J. J., & Campbell, R. K.
Venue
Annals of Pharmacotherapy
Published
2009-07-28
Volume
43
Issue
9
Pages
1433-1444
ISSN
  • 0012-6578 (ISSN-L)
  • 1060-0280
  • 1542-6270
OpenAlex
W2111901007
Cited by
63
References
19
FWCI
4.57
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.